Bispecific Antibody Combination Active in Metastatic HR+/HER2+ Breast Cancer

(MedPage Today) -- SAN ANTONIO -- Combination therapy including a bispecific antibody targeting HER2 showed durable activity in patients with previously treated metastatic hormone receptor-positive (HR+)/HER2+ breast cancer, a preliminary clinical...
Source: MedPage Today OB/GYN - Category: OBGYN Source Type: news